Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Theft Case Against Viscotek to Proceed

By Drug Discovery Trends Editor | September 3, 2009

Wyatt Technology Corporation, a leader in instruments for absolute macromolecular characterization, announces that the U.S. Court of Appeals for the Ninth Circuit reversed the summary judgment of the Federal district court and reinstated Wyatt’s conversion (theft) claims against Viscotek, a Malvern Company, for DynaPro-related assets and for Viscotek’s violations under the Lanham Act.

The Ninth Circuit also reversed damages previously awarded to Viscotek.

Wyatt’s lawsuit seeks damages in excess of $5 Million arising from Viscotek’s theft of Protein Solutions assets which included domain names, test equipment, customer databases, and other items-all of which were purchased by Wyatt in a court-administered auction in November 2004.

Wyatt Technology is a Santa Barbara, California-based company that develops and commercializes instrumentation used for the absolute characterization of macromolecules and nanoparticles in solution. In late 2004 Wyatt successfully outbid Malvern at the court-directed liquidation to purchase the assets of Proterion Corporation (Protein Solutions), which had ceased operations. The assets included the DynaPro instrument product line among other assets, which are used worldwide to characterize the solution behavior of biomolecules.

Dr. Philip Wyatt, the CEO of Wyatt Technology, stated: “We are very pleased that we will have the opportunity at last to recover the property taken by Viscotek and obtain the appropriate financial compensation for damages.”

Geofrey Wyatt, the Company President, added that Viscotek’s parent, Malvern Instruments USA, was being brought to trial by Wyatt within the next two months on similar illegal conduct including theft of trade secrets. “We are seeking damages from Malvern in excess of $25 million.”

Date: September 1, 2009
Source: Wyatt Technology 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE